Intercept Pharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and other product candidates in various stages of clinical and preclinical development. It has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. The company markets its products through an internal commercial organization, a contract sales organization, and third-party distributors. Intercept Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in New York, New York. Show More...
-
Website http://www.interceptpharma.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 0.00 USD
-
Last Updated 20-11-2023
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share USD -5.4 -4.73 -7.36 -3.76 -13.63 -9.56 -16.74 -14.38 -10.86 -10.89 -10.72 Dividends USD Payout Ratio % * Shares Mil 3.0 3.0 6.0 18.0 21.0 24.0 25.0 25.0 28.0 32.0 32.0 Book Value Per Share * USD 3.99 4.69 12.19 27.79 16.72 4.43 3.23 3.98 -1.05 Free Cash Flow Per Share * USD -2.51 -1.14 -3.51 -5.91 -13.16 -11.6 -9.68 -7.45 Return on Assets % -80.83 -70.3 -51.65 -140.05 -49.77 -59.19 -58.9 -62.25 -54.54 -63.13 Financial Leverage (Average) 1.7 1.82 1.1 1.08 2.35 29.56 26.62 14.64 Return on Equity % -146.15 -91.42 -180.8 -54.36 -90.03 -217.54 -975.25 Return on Invested Capital % -146.15 -91.42 -180.8 -54.36 -49.84 -64.39 -73.11 -61.51 Interest Coverage -28.08 -11.31 -9.13 -7.38 -6.71 Current Ratio 4.69 8.62 16.61 16.13 13.55 9.02 4.31 4.22 4.45 4.19 Quick Ratio 4.55 8.55 16.47 15.9 13.34 8.94 4.17 4.04 4.26 3.95 Debt/Equity 1.08 21.71 19.41 10.32